GLP-1激动剂对睡眠障碍的影响:聚焦睡眠呼吸暂停
Caroline S Mifsud1, Bhanu Prakash Kolla2,3, David R Rushlow1
1Department of Family Medicine, Mayo Clinic, Rochester, MN, USA.
Expert opinion on pharmacotherapy
|October 20, 2025
概括
蒂尔泽帕提德是FDA批准用于阻塞性睡眠呼吸暂停 (OSA) 的第一个药物. 这标志着向重量为中心的疾病修饰策略的转变,可能改变慢性OSA管理.
科学领域:
- 药理学 药理学是指药理学的学科.
- 睡眠医学 睡眠医学
- 代谢性疾病 代谢性疾病
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 传统上是通过持续正气道压力 (CPAP) 来管理的.
- 美国食品和药物管理局 (FDA) 最近批准了tirezepatide用于OSA治疗.
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 正在成为OSA的新治疗类.
研究的目的:
- 审查GLP-1RA对OSA治疗的影响.
- 在SURMOUNT-OSA试验的基础上,对OSA的蒂尔泽帕提德的FDA批准进行背景化.
主要方法:
- 对GLP-1RA和OSA的当前文献的综述.
- 分析SURMOUNT-OSA试验结果的影响.
- 讨论OSA管理范式的转变.
主要成果:
- 蒂尔泽帕提德的FDA批准意味着从症状管理转向疾病修改.
- 在OSA中GLP-1RA的益处可能包括减肥和直接的呼吸系统影响.
- 药物治疗为个人化OSA管理提供了潜在的潜力,因为OSA是一种慢性代谢疾病.
结论:
- 蒂尔泽帕提德的批准代表了OSA药物治疗的重大进展.
- 未来的OSA管理可能会越来越多地关注代谢方面和个性化治疗策略.
- GLP-1RA正在准备在OSA患者的慢性护理中发挥关键作用.
相关概念视频
Sleep Apnea
475
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
475
Glucagon-like Receptor Agonists
840
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
840
Management of Insomnia
528
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
528
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
522
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
522
Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581
Sedatives and Hypnotics Drugs: Miscellaneous Agents
508
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
508


